Joel Isaacson & Co’s Quest Diagnostics DGX Stock Holding History

Joel Isaacson & Co’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-107	Closed	-$10K	–	268
2016 Q4	$10K	Hold	107	–	–	﹤0.01%	497
2016 Q3	$9K	Buy	107 +1	+0.9%	+$84	﹤0.01%	551
2016 Q2	$9K	Hold	106	–	–	﹤0.01%	547
2016 Q1	$8K	Buy	106 +1	+1%	+$67	﹤0.01%	602
2015 Q4	$7K	Buy	105 +1	+1%	+$67	﹤0.01%	588
2015 Q3	$6K	Hold	104	–	–	﹤0.01%	612
2015 Q2	$8K	Buy	104 +1	+1%	+$74	﹤0.01%	611
2015 Q1	$8K	Hold	103	–	–	﹤0.01%	586
2014 Q4	$7K	Buy	103 +1	+1%	+$63	﹤0.01%	527
2014 Q3	$6K	Hold	102	–	–	﹤0.01%	519
2014 Q2	$6K	Buy	102 +1	+1%	+$59	﹤0.01%	493
2014 Q1	$6K	Hold	101	–	–	﹤0.01%	493
2013 Q4	$5K	Buy	101 +1	+1%	+$59	﹤0.01%	457
2013 Q3	$6K	Buy	+100	New	+$5.99K	﹤0.01%	435

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Joel Isaacson & Co's DGX Position: Q1 2017 in Review

Joel Isaacson & Co sold out of Quest Diagnostics (DGX) in Q1 2017, closing a stake of 107 shares — an estimated $10K sold.

Joel Isaacson & Co first reported a position in DGX in Q3 2013 and held it in 14 quarters. The position peaked at $10K in Q4 2016. 614 funds tracked by Wall St. Rank hold DGX as of Q1 2017.

Joel Isaacson & Co reported no remaining Quest Diagnostics position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 107 Quest Diagnostics shares in Q1 2017, an estimated $10K.
Joel Isaacson & Co first reported a position in Quest Diagnostics in Q3 2013 and held it in 14 quarters.
Joel Isaacson & Co's Quest Diagnostics position peaked at $10K in Q4 2016.
614 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.